medigraphic.com
ISSN 2448-8747 (Print)
Publicación cuatrimestral editada por la Secretaría de Salud Jalisco

2025, Number 3

<< Back Next >>

Sal Jal 2025; 12 (3)

Antimicrobial sensitivity to group A beta-hemolytic streptococcus (GABHS) of strains from children under 6 years of age

Reyes-Gómez U, Reyes-Hernández KL, Reyes-Hernández MU, Coria-Lorenzo JJ, Quero-Hernández A, Aguilar-Figueroa S, Ayuzo-del VC, Flores-Martínez MF, Linares-García R, Ojeda-Robledo LA, Pérez-Ortega FP, Balderas-Cacho X

Language: Spanish
References: 17
Page: 161-165
PDF size: 444.47 Kb.


ABSTRACT

Introduction: pharyngitis and pharyngotonsillitis t are common infections in the pediatric population, with group A beta-hemolytic streptococcus (GABHS) being the predominant bacterial agent. It is responsible for severe infections such as necrotizing fasciitis and toxic shock syndrome. This study aims to assess the antimicrobial sensitivity and resistance of GABHS in a private clinic in Oaxaca over a period of 4 years. Materials and methods: a qualitative, quantitative, prospective, and comparative study was conducted on isolates obtained from children attending a second-level hospital. Results: strains of group A beta-hemolytic streptococcus were analyzed, yielding the following sensitivity results to various antibiotics: amoxicillin 100%, 100%, 100%, and 70%, ampicillin 0%, 50%, 100%, and 0%, cefalotin 100%, 50%, 40%, and 60%, cefazolin 66%, 75%, 80%, and 80%, cefotaxime 100%, 0%, 0%, and 0%, ciprofloxacin 100%, 94%, 100%, and 80%, clindamycin 33%, 94%, 40%, and 70%, erythromycin 33%, 75%, 60%, and 20%, gentamicin 0%, 38%, 20%, and 10%, imipenem 0%, 6%, 0%, and 10%, nitrofurantoin 0%, 0%, 0%, and 20%, norfloxacin 0%, 31%, 40%, and 100%, oxacillin 66%, 87%, 100%, and 80%, penicillin 100%, 100%, NR, and 80%, rifampicin 33%, 87%, 40%, and 30%, tetracycline 100%, 94%, 80%, and 50%. Conclusion: in our setting, group A beta-hemolytic streptococcus demonstrates high sensitivity to amoxicillin (70-100%) and ciprofloxacin (80-100%), and variable sensitivity to erythromycin (20-75%) These findings are important for guiding therapy and appropriate treatment for various pathologies caused by this pathogen.


REFERENCES

  1. Danté R, Manzanares LS, Lafuente VS. Brote de faringoamigdalitis por estreptococo β-hemolítico del grupo A. Rev Saúde Pública. 2014;48(2):322-325.

  2. García M. Comportamiento de los estreptococos beta-hemolíticos en escolares. Sanid Mil. 2012;68(1):17-21.

  3. Lopardo G, Calmaggi A, Clara L. Consenso sobre diagnóstico y tratamiento de infecciones de vías respiratorias. Medicina (B Aires). 2012;72(6):484-494.

  4. Del Rio ACN, Rivera SG, Lopez LME. Varicela e infección por estreptococo beta-hemolítico del grupo A. Importancia de un diagnóstico oportuno. Acta Pediatr Mex. 2012;33(1):32-37.

  5. World Health Organization. The current evidence for the burden of group A streptococcal diseases: WHO report. Geneva: World Health Organization; 2005.

  6. Sheel M, Licciardi PV, Guy R, Carapetis JR. Development of group A streptococcal vaccines: an unmet global health need. Expert Rev Vaccines. 2016;15(2):227-238.

  7. Kaneko M, Maruta M, Shikata H, Hanayama M, Ikebe T. Acute abdomen due to group A Streptococcus bacteremia caused by an isolate with a mutation in the csrS gene. J Infect Chemother. 2015;21(11):816-819.

  8. Matsumoto M, Yamada K, Suzuki M, Adachi H, Kobayashi S, Yamashita T, et al. Description of the pathogenic features of Streptococcus pyogenes isolates from invasive and non-invasive diseases in Aichi, Japan. Jpn J Infect Dis. 2016;69(4):338-341.

  9. Steer AC, Law I, Matatolu L, Beall BW, Carapetis JR. Global EMM type distribution of group A streptococci: systematic review and implications for vaccine development. Lancet Infect Dis. 2009;9(10):611-616. doi: 10.1016/S1473-3099(09)70178-1.

  10. Towers RJ, Galasso GJ, McAlister J, Farkouh RA. Increasing rate of group A streptococcus and methicillin-resistant Staphylococcus aureus infections in children. J Pediatr Surg. 2011;46(12):2222-2225. doi: 10.1016/j.jpedsurg.2011.07.032.

  11. Carapetis JR, Steer AC, Mulholland EK, Weber M. The global burden of group A streptococcal diseases. Lancet Infect Dis. 2005;5(11):685-694. doi: 10.1016/S1473-3099(05)70267-X.

  12. Sagar S, Das SS, Laxmi P, Verma S, Singh R, Kumar M, et al. Antimicrobial susceptibility patterns of Streptococcus pyogenes over 5 years from a tertiary care centre in North India. Indian J Med Microbiol. 2017;35(3):397-401. doi: 10.4103/ijmm.IJMM_17_206.

  13. Shea PR, Beres SB, Flores AR, Ewbank AL, Gonzalez-Lugo JH, Martagon-Rosado AJ, et al. Distinct signatures of diversifying selection revealed by genome analysis of respiratory tract and invasive bacterial populations. Proc Natl Acad Sci U S A. 2011;108(12):5039-5044. doi: 10.1073/pnas.1016282108.

  14. Lamagni TL, Darenberg J, Luca-Harari B, Siljander T, Efstratiou A, Henriques-Normark B, et al. Epidemiology of severe Streptococcus pyogenes disease in Europe. J Clin Microbiol. 2008;46(7):2359-2367. doi: 10.1128/JCM.00422-08.

  15. Megged O. Characteristics of Streptococcus pyogenes versus Streptococcus pneumoniae pleural empyema and pneumonia with pleural effusion in children. Pediatr Infect Dis J. 2020;39(9):799-802. doi: 10.1097/INF.0000000000002699.

  16. Nelson GE, Pondo T, Toews KA, Farley MM, Lindegren ML, Lynfield R, et al. Epidemiology of invasive group A streptococcal infections in the United States, 2005-2012. Clin Infect Dis. 2016;63(4):478-486. doi: 10.1093/cid/ciw248.

  17. Kebede D, Admas A, Mekonnen D. Prevalence and antibiotic susceptibility profiles of Streptococcus pyogenes among pediatric patients with acute pharyngitis at Felege Hiwot comprehensive specialized hospital, Northwest Ethiopia. BMC Microbiol. 2021;21(1):1-10. doi: 10.1186/s12866-021-02196-0.




2020     |     www.medigraphic.com